DKA Capital, founded in 1984, is a prominent Danish private equity firm that specializes in investing in and developing knowledge-intensive growth companies with global potential. The firm has a strong track record, having completed 180 investments and 175 exits, including 21 initial public offerings. DKA Capital focuses on buyout investments, particularly in technology companies within Western Europe. The firm aims to create long-term sustainable value through strategic ownership and constructive communication with portfolio companies. In 2011, DKA Capital, alongside Norwegian Argentum, acquired a significant stake in DKA II, which currently holds five companies in its portfolio. DKA Capital is recognized as one of Denmark's leading private equity funds, committed to maintaining its position as a credible partner for businesses with international growth opportunities.
CanopyLAB is an educational technology company with a mission to change the way we learn and offer a platform for learning that is available to all types of companies and organizations. Our office is located in Copenhagen, Denmark and our mission is to conquer the world. The Canopy is where we design white label solutions for corporate learning and communication. The LAB offers free and global learning with leading NGOs on focusing on the UN 17 Sustainable Development Goals and humanities.
Secunia ApS develops vulnerability management, security patching, and personal computer security software solutions for financial service, government, education, energy and utility, healthcare, and other markets. It serves customers in Denmark and internationally. The company was founded in 2002 and is based in Copenhagen, Denmark. As of September 11, 2015, Secunia ApS operates as a subsidiary of Flexera Software LLC.
KA Interiør A/S manufactures sliding-door wardrobes and cupboards. It produces cupboards for bedrooms, children's rooms, kitchens, hobby rooms, and offices. The company also offers mobile wall systems. It markets its products through independent kitchen and furniture outlets, and distributors in Denmark, Norway, Sweden, Germany, Iceland, and the Faeroe Islands. The company was founded in 1991 and is based in Grindsted, Denmark. As of June 20, 2018, KA Interiør A/S operates as a subsidiary of Vivonio Furniture GmbH.
Hymite is a venture funded product company bringing to market the next generation packaging platform for use with High Power (HP) / Ultra-high Brightness (UHB) LEDs. Hymite's Engineered Silicon (Si) package platform delivers new levels of performance and value to their customers developing products for Solid State Lighting applications.
NsGene is a Danish Biotech company located in the Medicon Valley region. The Company is committed to developing novel biological products for the treatment of neurological diseases and is focusing on multiple indications with high unmet needs, including Alzheimer's disease, epilepsy, neuropathic pain and Parkinson's disease.
Direct Conversion AB specializes in the research, development, manufacturing, and marketing of advanced X-ray imaging sensors that utilize photon counting and hybridized semiconductor technology. Its products cater to various sectors, including dental, medical, welding, food, security, and industrial applications. The company offers a range of photon counting products under the XCounter brand, including the XC-Hydra, XC-Thor, XC-TDI, and XC-Actaeon series. Additionally, it provides charge integrating detectors under the AJAT brand, featuring models such as SNAP 225 and ARISTO. Direct Conversion also develops cadmium telluride direct conversion detectors. Founded in 1997 and headquartered in Danderyd, Sweden, the company operates additional offices in London, Espoo, and Munich. In December 2016, it changed its name from XCounter AB to Direct Conversion AB and is currently a subsidiary of Varex Imaging Corporation.
Develogen is a biology-driven drug discovery company that is engaged in the development of therapies for diabetes and obesity. The company was founded in 1995 and is based in Georgia, United States.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
HepaVec AG
Series A in 2000
HepaVec AG is a privately held biotechnology company, focused on the development of novel therapeutic products for addressing malignant and genetic liver diseases, and on cell engineering of hepatocytes (liver cells). HepaVec has developed new gene transfer systems (vectors), derivatives of baculovirus and an ovine (sheep) adenovirus (OAV), which enable efficient and specific delivery of therapeutic genes into human liver cells. In the combat against liver cancer, HepaVec's lead product regulates the cell cycle to selectively drive cancer cells to programmed cell death (apoptosis) and is scheduled to enter a Phase I/II clinical trial in 2000.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.